Smith & Nephew SNATS, Inc. $SNN Shares Acquired by Tidal Investments LLC

Tidal Investments LLC increased its holdings in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 60.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 267,513 shares of the medical equipment provider’s stock after purchasing an additional 100,565 shares during the period. Tidal Investments LLC owned 0.06% of Smith & Nephew SNATS worth $7,707,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in SNN. WINTON GROUP Ltd purchased a new position in Smith & Nephew SNATS during the second quarter worth about $510,000. Engineers Gate Manager LP grew its holdings in Smith & Nephew SNATS by 26.4% in the 2nd quarter. Engineers Gate Manager LP now owns 13,002 shares of the medical equipment provider’s stock valued at $375,000 after buying an additional 2,714 shares during the period. Allworth Financial LP increased its stake in shares of Smith & Nephew SNATS by 94.8% during the 2nd quarter. Allworth Financial LP now owns 2,965 shares of the medical equipment provider’s stock valued at $85,000 after acquiring an additional 1,443 shares during the last quarter. Corient Private Wealth LP increased its stake in shares of Smith & Nephew SNATS by 3.7% during the 2nd quarter. Corient Private Wealth LP now owns 26,018 shares of the medical equipment provider’s stock valued at $750,000 after acquiring an additional 932 shares during the last quarter. Finally, Plan A Wealth LLC lifted its holdings in shares of Smith & Nephew SNATS by 16.5% during the 2nd quarter. Plan A Wealth LLC now owns 8,607 shares of the medical equipment provider’s stock worth $248,000 after acquiring an additional 1,221 shares during the period. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SNN has been the topic of several research analyst reports. Wall Street Zen raised shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research report on Sunday. Morgan Stanley lowered shares of Smith & Nephew SNATS from an “overweight” rating to an “equal weight” rating in a research report on Wednesday, September 2nd. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Smith & Nephew SNATS in a research note on Thursday, August 6th. Kepler Capital Markets lowered shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Finally, Weiss Ratings raised shares of Smith & Nephew SNATS from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, September 4th. One research analyst has rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $31.91.

Smith & Nephew SNATS Price Performance

Smith & Nephew SNATS stock opened at $27.50 on Friday. The stock’s 50-day moving average is $29.94 and its 200-day moving average is $31.17. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14. Smith & Nephew SNATS, Inc. has a 12 month low of $27.23 and a 12 month high of $38.44.

Smith & Nephew SNATS Announces Dividend

The firm also recently announced a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be given a dividend of $0.312 per share. This represents a yield of 205.0%. The ex-dividend date of this dividend is Friday, October 2nd.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company headquartered in the United Kingdom. Founded in 1856 by Thomas James Smith in Hull, the company initially operated as a pharmacy business before expanding into healthcare products and medical devices.

The company develops and manufactures technologies used in orthopaedic reconstruction, sports medicine, and advanced wound management. Its products include joint replacement systems, trauma and extremities devices, arthroscopic equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products designed to support tissue healing and surgical care.

Smith & Nephew serves hospitals, healthcare professionals, and patients in markets around the world.